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AbstrACt
Objectives To describe the frequency and nature of 
symptoms in patients presenting with suspected renal cell 
carcinoma (RCC) and examine their reliability in achieving 
early diagnosis.
Design Multicentre prospective observational cohort 
study.
setting and participants Eleven UK centres recruiting 
patients presenting with suspected newly diagnosed 
RCC. Symptoms reported by patients were recorded 
and reviewed. Comprehensive clinico- pathological and 
outcome data were also collected.
Outcomes Type and frequency of reported symptoms, 
incidental diagnosis rate, metastasis- free survival and 
cancer- specific survival.
results Of 706 patients recruited between 2011 and 
2014, 608 patients with a confirmed RCC formed the 
primary study population. The majority (60%) of patients 
were diagnosed incidentally. 87% of patients with stage Ia 
and 36% with stage III or IV disease presented incidentally. 
Visible haematuria was reported in 23% of patients and 
was commonly associated with advanced disease (49% 
had stage III or IV disease). Symptomatic presentation 
was associated with poorer outcomes, likely reflecting the 
presence of higher stage disease. Symptom patterns among 
the 54 patients subsequently found to have a benign renal 
mass were similar to those with a confirmed RCC.
Conclusions Raising public awareness of RCC- related 
symptoms as a strategy to improve early detection rates 
is limited by the fact that related symptoms are relatively 
uncommon and often associated with advanced disease. 
Greater attention must be paid to the feasibility of 
screening strategies and the identification of circulating 
diagnostic biomarkers.
IntrODuCtIOn
The incidence of kidney cancer in Europe 
is among the highest worldwide. In the UK, 
incidence rates have risen by 47% over the 
past decade, with 12 000 new cases in 2015.1 
By 2035, it is predicted that this number will 
rise to over 20 000 new cases per annum and 
kidney cancer will come to represent the 
fourth most common cancer among men 
and ninth most common among women in 
the UK.2
Diagnosing patients with kidney cancer 
can be challenging.3 Renal cell carcinomas 
(RCCs), which make up the majority (85%) 
of kidney cancers, are characteristically 
insidious in onset. The once classical triad 
of haematuria, pain and abdominal mass is 
now recognised to be rare, and symptoms, 
if present at all, can be vague, non- specific 
and delayed in onset. While early diagnosis 
is recognised to be key in achieving optimal 
strengths and limitations of this study
 ► The multicentre, prospective nature of this study, 
among a contemporary cohort of UK patients, is 
unique and represents an important strength over 
previous studies.
 ► Comprehensive linked clinico- pathological and out-
come data were available for all patients.
 ► Symptoms among patients subsequently found to 
have a benign renal mass are reported in parallel.
 ► This was not a population- based study and our co-
hort represents only a small proportion of all patients 
diagnosed with renal cell carcinoma in the UK within 
the study period.
 ► Patient- reported symptoms were recorded follow-
ing referral to secondary care and may therefore be 
subject to recall bias.
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Figure 1 Flowchart of patients through the study. RCC, 
renal cell carcinoma.
outcomes, many patients still present with advanced 
disease. In 2017 in England, for example, figures show 
that among patients with a recorded stage at diagnosis, 
19% had stage III and 23% had stage IV disease, at the 
time of presentation.4
Campaigns to raise awareness of kidney cancer among 
the public and doctors have been employed in an effort 
to improve early diagnosis rates.5 Understanding how 
patients present may help to inform such strategies. 
Unlike previous studies, we prospectively collected infor-
mation on symptoms reported by patients at the time of 
their diagnosis of suspected RCC, following recruitment 
to a large, contemporary, multi- institutional UK RCC 
biobank.6 The aims of this substudy were to describe 
symptoms reported by patients, define the current rate 
of incidental diagnosis and look at how these factors 
relate to patient outcomes, with the goal of better under-
standing the challenges in early RCC diagnosis.
MethODs
The design was a multicentre prospective observational 
cohort study. Patients with a renal mass on imaging suspi-
cious of RCC, of all stages, with no prior treatment, were 
eligible. Patients were approached and consented to 
participate in the study prior to surgery or biopsy, before 
diagnosis of RCC was confirmed. Full details regarding 
the inclusion and exclusion criteria are as previously 
reported.6 Comprehensive clinical and pathological 
information was collected.
At the time of recruitment to the study, patients were 
asked about the presence and nature of symptoms leading 
to their diagnosis of suspected RCC, which was recorded 
using paper case report forms (CRF). Specific informa-
tion relating to commonly related ‘RCC- type’ local symp-
toms (pain, haematuria, abdominal mass and/or other) 
and systemic symptoms (weight loss (any), loss of appe-
tite, sweats, fevers, fatigue and/or other) was recorded. In 
addition, the investigator completing the CRF was asked 
to state whether the diagnosis was incidental in nature 
and included a subsequent free- text box requesting a 
description of how the patient was diagnosed. All cases 
were independently reviewed by two reviewers (NSV and 
REB) to confirm or refute whether the diagnosis would 
be regarded as incidental or not (ie, were any symptoms 
reported and, if so, would they be regarded as being 
related to the finding of RCC), with additional reference 
to individual electronic case notes where available. The 
reported presence of RCC- type symptoms, many of which, 
such as pain, are non- specific, was not always related to the 
finding of RCC and, where applicable, therefore, consid-
ered incidental. Cases with insufficient data or where the 
incidental nature of the diagnosis remained uncertain 
were not classified. Patients being investigated for asymp-
tomatic hypertension were not classified as incidental.7
Metastasis- free survival (MFS) was calculated for patients 
with localised disease, defined as the period from the date 
of nephrectomy to the date of distant recurrence. Patients 
without recurrence were censored at the date they were 
last known to be recurrence- free (for patients who died 
without recurrence this was the date of death). Cancer- 
specific survival (CSS) was defined as the period from the 
date of nephrectomy to the date of cancer- related death. 
Patients with a non- cancer related death were censored at 
their date of death and patients still alive were censored 
at the last date they were known to be alive. Kaplan- Meier 
plots were produced to visualise survival and the log- rank 
test was used to detect a statistically significant difference 
between survival curves.
Public and patient involvement
Patients were extensively involved in the design, delivery 
and evaluation of the NIHR Programme supporting this 
work. Patients were not directly involved in the design or 
evaluation of the current report.
results
Between July 2011 and June 2014, 706 patients were 
recruited to the study from 11 UK centres (8 England, 
2 Scotland, 1 Wales). Details regarding recruitment 
by centre are shown in online supplementary table 
1. The flow of patients through the study is shown in 
figure 1. RCC was confirmed in 608 (86%) patients, 
among whom median follow- up was 4.8 years (IQR: 3.7, 
5.2), and benign renal mass in 54 (7.6%) patients. The 
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Table 1 Patient and tumour characteristics by symptom type for continuous variables, figures in table represent median 
(range) with corresponding p value from the Kruskal- Wallis test and for categorical variables, figures in table represent n (%) 
with corresponding p value from the χ2 test
Characteristic
No RCC- type 
symptoms (n=186)
RCC- type symptoms reported (n=422)†
Not RCC related 
(n=183)
RCC- related local 
symptoms only 
(n=97)
RCC- related 
systemic symptoms 
(±local) (n=124) P value
Age (years) 65 (31–86) 63 (29–90) 63 (38–84) 62 (33–92) 0.31
Gender         
  Female 67 (32.7) 62 (30.2) 21 (10.2) 55 (26.8)
  Male 119 (30.9) 121 (31.4) 76 (19.7) 69 (17.9) 0.01
BMI 28.5 (15.6–74.4) 27 (18.1–56.5) 28.8 (17.3–67.2) 27.5 (16–54.5) 0.01
Tumour size (mm) 44 (14–180) 43 (11–170) 74 (13–155) 75 (20–240) <0.01
pT         
  1a 83 (42.6) 88 (45.1) 16 (8.2) 8 (4.1)
  1b 46 (34.3) 42 (31.3) 19 (14.2) 27 (20.1)
  2 15 (19.7) 18 (23.7) 19 (25) 24 (31.6)
  3 38 (22.6) 33 (19.6) 42 (25) 55 (32.7)
  4 0 (0) 0 (0) 1 (25) 3 (75)
  X 1 (50) 1 (50) 0 (0) 0 (0)
  Missing 1 (100) 0 (0) 0 (0) 0 (0)
  NA 2 (20) 1 (10) 0 (0) 7 (70) <0.01
Grade         
  1 4 (40) 0 (0) 4 (40) 2 (20)
  2 55 (34.8) 50 (31.6) 25 (15.8) 28 (17.7)
  3 88 (32.2) 94 (34.4) 47 (17.2) 44 (16.1)
  4 13 (14.9) 13 (14.9) 19 (21.8) 42 (48.3)
  Missing 9 (39.1) 9 (39.1) 1 (4.3) 4 (17.4)
  NA 17 (43.6) 17 (43.6) 1 (2.6) 4 (10.3) <0.01
Stage         
  I 130 (39.8) 129 (39.4) 34 (10.4) 34 (10.4)
  II 12 (17.4) 17 (24.6) 18 (26.1) 22 (31.9)
  III 34 (24.5) 29 (20.9) 37 (26.6) 39 (28.1)
  IV 10 (18.9) 6 (11.3) 8 (15.1) 29 (54.7)
  Missing 0 (0) 2 (100) 0 (0) 0 (0) <0.01
Tumour subtype         
  Clear cell 147 (31.7) 137 (29.6) 83 (17.9) 96 (20.7)
  Papillary 16 (27.1) 23 (39) 7 (11.9) 13 (22)
  Chromophobe 15 (32.6) 15 (30.4) 7 (15.2) 10 (21.7)
  Unclassified 7 (38.9) 6 (33.3) 0 (0) 5 (27.8)
  Other 1 (33) 2 (67) 0 (0) 0 (0) 0.81
*Not applicable (NA)—patients underwent biopsy only or tumour ablation.
†18 patients reported symptoms but their relationship to RCC could not be determined.
BMI, body mass index; RCC, renal cell carcinoma.
remaining 44 (6.4%) patients either did not undergo 
biopsy or nephrectomy or had no tumour in their biopsy 
cores (n=33), had another (not RCC) malignancy (n=5) 
or an alternative benign pathology (n=6).6 Among all 
patients with a confirmed RCC, 422 (69%) patients 
reported having RCC- type symptoms at diagnosis, of 
whom 221 (52%) reported symptoms that were consid-
ered related to the presence of RCC. Among these 221 
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Table 2 Patient and tumour characteristics by diagnosis 
type: for continuous variables, figures in table represent 
median (range) with corresponding p- value from the 
Wilcoxon rank- sum test, and for categorical variables, 
figures in table represent n (%) with corresponding p- value 
from the χ2 test
Characteristic
Non- incidental 
(n=231) Incidental (n=351) P value
Age (years) 62 (33–92) 65 (29–90) 0.04
Gender
  Female 77 (38.3) 124 (61.7)
  Male 154 (40.4) 227 (59.6) 0.69
BMI 28.3 (15.6–67.2) 27.8 (17.2–57.7) 0.38
Tumour size (path) 
(mm)
75 (13–240) 42 (11–170) <0.01
Tumour size (CT) 
(mm)
80 (16–250) 44 (10–170) <0.01
pT
  1a 25 (12.8) 170 (87.2)
  1b 48 (37.2) 81 (62.8)
  2 46 (60.5) 30 (39.5)
  3 101 (61.2) 64 (38.8)
  4 4 (100) 0 (0)
  X 0 (0) 2 (100)
  Missing 0 (0) 1 (100)
  NA* 7 (70) 3 (30) <0.01
Grade
  1 6 (66.7) 3 (33.3)
  2 56 (35.9) 100 (64.1)
  3 93 (34.6) 176 (65.4)
  4 65 (75.6) 21 (24.4)
  Missing 6 (26.1) 17 (73.9)
  NA* 5 (12.8) 34 (87.2) <0.01
Stage
  I 70 (21.6) 254 (78.4)
  II 42 (60.9) 27 (39.1)
  III 80 (58.4) 57 (41.6)
  IV 39 (78) 11 (22)
  Missing 0 (0) 2 (100) <0.01
Tumour subtype
  Clear cell 186 (40.9) 269 (59.1)
  Papillary 21 (35.6) 38 (64.4)
  Chromophobe 19 (41.3) 28 (58.7)
  Unclassified 5 (27.8) 13 (72.2)
  Other 0 (0) 3 (100) 0.62
*Not applicable (NA), patients underwent biopsy only or tumour ablation.
BMI, body mass index.
Table 3 Nature of incidental diagnosis
Type of incidental diagnosis n (%)
Investigation for pre- existing condition 65 (18)
  Another malignancy 34 (53)
  Diabetes mellitus 7 (11)
  Hepatobiliary* 5 (8)
  AAA screening/post- aortic repair 3 (5)
  Other† 16 (23)
Investigation for signs or symptoms unrelated to RCC 258 (74)
  Gastrointestinal‡ 86 (33)
  Urinary tract§ 49 (19)
  Hepatobiliary¶ 27 (10)
  Respiratory** 20 (8)
  Musculoskeletal†† 16 (6)
  Cardiovascular‡‡ 11 (4)
  Trauma 7 (3)
  Gynaecological 6 (3)
  Anaemia 4 (2)
  Miscellaneous§§ 32 (12)
Routine health check¶¶ 16 (5)
Not known*** 12 (3)
*Cirrhosis, primary biliary cirrhosis and sclerosing cholangitis.
†Includes Addison’s disease, chronic renal failure, Crohn’s disease, 
coeliac disease, ovarian cyst, renal stones, IgA nephropathy, 
Wegener’s granulomatosis, polymyalgia rheumatica and ovarian cyst.
‡Altered bowel habit, GI bleed, bloating/distension, abdominal pain 
and reflux.
§Urinary retention, prostatic symptoms, high prostate- specific antigen, 
urosepsis, renal colic and impaired renal function.
¶Biliary colic, deranged liver function tests, jaundice, pancreatitis and 
cholecystitis.
**Shortness of breath, cough, haemoptysis and pneumonia.
††Back pain, leg pain and joint pain.
‡‡Chest pain, myocardial infarction, claudication and endocarditis.
§§Includes dizziness, syncope, elevated blood test values and ankle 
swelling.
¶¶Initial investigations were urine dip (6), ultrasound scan (5), CT scan 
(2), blood tests (2) and chest x- ray (1).
***Insufficient information to classify.
AAA, abdominal aortic aneurysm; RCC, renal cell carcinoma.
patients, 97 (44%) had local symptoms only, 19 (8.6%) 
had systemic symptoms only and 105 (47.5%) reported 
having both local and systemic symptoms. Patient and 
tumour characteristics by symptom type are shown in 
table 1.
local rCC-related symptoms
Among the 202 (33%) patients reporting local RCC- 
related symptoms, 137 (68%) reported visible haema-
turia and 126 (62%) reported pain, with only 14 
(7%) patients reporting an abdominal mass. Patients 
presenting with haematuria had a median patholog-
ical tumour size of 75 mm (range 16–155) and almost 
half had stage III (37.2%) or IV (12.4%) disease. Only 
four patients (0.6%) presented with the classical triad 
of an abdominal mass, haematuria and local pain. The 
median tumour size among these four patients was 105 
mm (range 80–154 mm) on preoperative cross- sectional 
imaging. No significant differences were present when 
considered by histological type, although the small 
number of patients with non- clear cell RCC limits this 
comparison.
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Figure 2 Kaplan Meier survival curves by symptom type. Survival outcomes ((A) MFS; (B) CSS) in patients with no RCC- 
type symptoms, unrelated RCC- type symptoms, local RCC- related symptoms and those with systemic (± local) RCC- related 
symptoms. CSS, cancer- specific survival; MFS, metastasis- free survival; RCC, renal cell carcinoma.
systemic rCC-related symptoms
Among those reporting systemic symptoms related to their 
RCC, fatigue (62%), weight loss (52%), sweats (38%) and 
loss of appetite (38%) were all commonly reported. Fever 
was relatively uncommon (10%). Patients with systemic 
symptoms were more likely to have grade 4 cancers and 
stage IV disease than those with local RCC- related symp-
toms only and those with symptoms unrelated to RCC 
(p<0.01) (table 1).
Incidental diagnosis
Among the 582 patients in whom the nature of the diag-
nosis could be confidently classified, 351 (60%) cases of 
RCC were deemed to have been diagnosed incidentally. 
Patient and tumour characteristics by nature of diagnosis 
(incidental vs non- incidental) are shown in table 2. No 
association with patient sex was found and distribution 
of histological subtype was similar between groups. Non- 
incidentally detected tumours were larger and of higher 
grade and stage than incidentally detected tumours 
(p<0.01). Among patients diagnosed with a localised pT1a 
tumour, the incidental diagnosis rate was 87%. Conversely, 
22% of patients with stage IV disease were considered to 
have been diagnosed incidentally. The nature of the inci-
dental diagnosis (eg, during investigation for a known 
pre- existing condition vs investigation of unrelated symp-
toms) is shown in table 3.
tumour size
Pathological tumour size was available for 556 (91%) of 
patients. We looked at symptoms in patients presenting 
with tumours ≥10 cm. Among the 66 patients with a 
tumour ≥10 cm, 31 (47%) reported haematuria at the 
time of presentation, 33 (50%) reported pain and abdom-
inal mass was reported in four (6%) patients. Almost a 
quarter (16/66; 24%) of these patients were considered 
to have been diagnosed incidentally, with 10 (15%) 
reporting no symptoms, despite the presence of a large 
primary tumour. No effect of BMI was observed in rela-
tion to presence or absence of symptoms.
Outcomes
We looked at survival outcomes by both symptom type 
(no RCC- type symptoms or unrelated RCC- type symp-
toms vs related RCC- type symptoms) and incidental vs 
non- incidental diagnosis. Patients diagnosed with no 
RCC- type symptoms and those reporting unrelated RCC- 
type symptoms had a significantly improved MFS and 
CSS compared with patients with related RCC- type symp-
toms. Furthermore, patients with systemic RCC- related 
6 Vasudev NS, et al. BMJ Open 2020;10:e035938. doi:10.1136/bmjopen-2019-035938
Open access 
Figure 3 Kaplan- Meier survival curves by incidental versus non- incidental diagnosis for all patients, stage I/II or stage III RCC. 
(A–C) MFS; (D–F) CSS. CSS, cancer- specific survival; MFS; metastasis- free survival; RCC, renal cell carcinoma.
symptoms had poorer outcomes than those with local 
RCC symptoms only (figure 2A,B). Overall, patients with 
an incidental diagnosis of RCC had improved MFS and 
CSS in comparison to those diagnosed non- incidentally, 
although it is important to note that these effects were 
lost when controlled for stage of disease (figure 3).
Patients presenting with benign renal masses
In total, 54 (7.6%) patients in our cohort were found 
to have a benign renal mass, composed of oncocytoma 
(n=29), angiomyolipoma (n=8) and other lesions (n=17) 
(table 4). The incidental diagnosis rate was 56% among 
the 52 evaluable patients. Haematuria and pain were 
reported, respectively, in 57% and 52% of patients diag-
nosed non- incidentally. The majority (65%) reported 
symptoms, of whom 57% had local symptoms only, 17% 
had systemic symptoms only and 26% reported both local 
and systemic symptoms.
DIsCussIOn
Early detection is widely held to be a key strategy towards 
improving outcomes in patients with RCC.8 As in most 
solid cancers, disease stage and survival are closely linked, 
with 3 year CSS rates in our cohort, for example, of 99% 
and 47% for stage I and stage IV cancers, respectively 
(data not shown). Symptoms of kidney cancer such as 
visible haematuria and flank pain are well documented 
and NHS initiatives such as ‘be clear on cancer: blood 
in your pee’ campaign have been aimed at prompting 
the public to seek early medical attention.5 Nevertheless, 
many patients still present with overt or micro- metastatic 
disease. Understanding the type and frequency of symp-
toms patients with newly diagnosed RCC report is crit-
ical in beginning to address this issue and understand 
whether simply raising awareness among doctors and the 
public is sufficient or other strategies are needed.
Our study highlights the significant challenges in diag-
nosing patients with kidney cancer. Almost a third of 
patients in our cohort were symptomless at the time of 
diagnosis, among whom nearly a quarter (24%) had stage 
III or IV disease. Visible haematuria, a hallmark symptom 
of this disease, was recorded in just 23% of patients overall. 
Even among patients with large (≥10 cm) tumours, less 
than half (47%) reported haematuria as a symptom. Prior 
reports using UK general practice database records have 
suggested rates of haematuria as low as 18% in patients 
presenting with kidney cancer, compounded by the low 
positive predictive value (PPV) (1%) of this symptom for 
RCC among those ≥60 year old.9 Furthermore, symptom 
patterns do not appear to reliably distinguish patients 
with benign renal masses from those with RCC.
Many studies have attempted to document the inci-
dental diagnosis rate for renal cancer. These previous 
studies have all been retrospective in nature, typically 
derived from patients at a single centre, with widely 
varying rates of incidental diagnosis, from 15% to 61%, 
in a less contemporaneous setting (broadly spanning 
1970–2000).10–14 A more recent, global, study, involving 
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Table 4 Characteristics and symptoms associated with benign renal masses
Characteristic All (n=54) Oncocytoma (n=29) AML (n=8) Other* (n=17)
Age (years) 65 (32–86) 66 (42–86) 63 (59–68) 61 (32–78)
Gender
  Female 29 (53.7) 12 (41.4) 5 (62.5) 12 (70.6)
  Male 25 (46.3) 17 (58.6) 3 (37.5) 5 (29.4)
BMI 27.6 (18.7–45.8) 27.8 (19.4–39.6) 28 (22–38.8) 26.4 (18.7–45.8)
CT size (cm)
  ≤4 22 (44.9) 14 (50) 3 (50) 5 (33.3)
  4< to ≤7 18 (36.7) 11 (39.3) 2 (33.3) 5 (33.3)
  7< to ≤10 6 (12.2) 1 (3.6) 1 (16.7) 4 (26.7)
  >10 3 (6.1) 2 (7.1) 0 (0) 1 (6.7)
  NA 5 (-) 1 (-) 2 (-) 2 (-)
RCC- type symptoms
  No 19 (35.2) 10 (34.5) 4 (50) 5 (29.4)
  Yes 35 (64.8) 19 (65.5) 4 (50) 12 (70.6)
Local symptoms
  No 6 (17.1) 3 (15.8) 1 (25) 2 (16.7)
  Yes 29 (82.9) 16 (84.2) 3 (75) 10 (83.3)
Systemic symptoms
  No 20 (57.1) 12 (63.2) 1 (25) 7 (58.3)
  Yes 15 (42.9) 7 (36.8) 3 (75) 5 (41.7)
Incidental diagnosis
  No 23 (42.5) 13 (44.8) 2 (25) 8 (47)
  Yes 29 (54) 15 (51.7) 6 (75) 8 (47)
  Not known 2 (3.5) 1 (3.5) 0 (0) 1 (6)
*Consists of cystic nephroma (4), benign cyst (3), metanephric adenoma (2), mixed epithelial stromal tumour (2), haemangioblastoma (1), leiomyomata 
(1), multilocular cyst (1), myxoid mesenchymal tumour (1), Rosai Dorfman disease (1), and solitary fibrous tumour (1).
AML, angiomyolipoma; BMI, body mass index; RCC, renal cell carcinoma.
4288 patients presenting with RCC between 2010 and 
2012, reported an incidental diagnosis rate of 67%.15 
However, no detail regarding how this was derived, or 
the nature and characteristics of those diagnosed inci-
dentally, were presented in this study. While retrospective 
studies have the advantage of being feasible on a large 
scale, often with long- term follow- up data, recording of 
symptoms at presentation may not have been performed 
for this purpose and may, therefore, not be complete. 
Furthermore, determining whether a diagnosis is inci-
dental or not can often require further detail beyond the 
recording of symptoms alone, and which may not always 
be available when records are reviewed retrospectively. 
Here, we collected symptoms reported by patients at diag-
nosis in a planned way as part of the study design using 
standardised CRFs, allowed for detailed free- text anno-
tation of the history leading to the diagnosis and asked 
investigators to specifically indicate whether this was felt 
to be incidental in nature. We carefully reviewed the 
presenting symptoms and history for each patient in our 
study, performed independently by two of the authors, to 
determine as accurately as possible whether the diagnosis 
would be deemed incidental or not. Pain, for example, 
was a commonly reported symptom not necessarily attrib-
utable to the diagnosis of RCC, for example, when located 
in an anatomically distinct site. We believe our figure of 
60%, among a contemporary set of patients (2011–2014), 
provides a true reflection of the current incidental diag-
nosis rate of RCC in the UK, and supports the general rise 
in the incidental detection of kidney cancer that has been 
reported over time.
Our data show that the majority (60%) of patients with 
RCC in the UK are being diagnosed incidentally, with 
almost three- quarters of these (74%) during investiga-
tion of symptoms unrelated to RCC. By contrast, a Norwe-
gian study of 413 patients diagnosed with RCC between 
1997 and 2010 reported a 53% incidental diagnosis rate, 
detected in 63% of these patients during follow- up for a 
pre- existing condition.16 The reason for this difference 
is not certain but may reflect the different time periods 
under study, given the more liberal use of cross- sectional 
imaging over time.17 Consistent with other studies, patients 
with an incidentally detected RCC tended to have smaller, 
lower stage and grade tumours than those presenting 
with related symptoms, but, nevertheless, almost one in 
five of patients identified incidentally had stage III/IV 
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disease at diagnosis. Whether patients who are diagnosed 
incidentally have better outcomes and potentially, there-
fore, different tumour biology, than those presenting 
with symptoms has been a matter of debate in the liter-
ature.10 18–20 We did not find any difference in MFS or 
CSS between these two groups when matched for stage of 
disease, suggesting that incidental detection of advanced 
stage disease is not advantageous in terms of outcome.
Diagnosing kidney cancer early is, therefore, a signif-
icant public health challenge. Data from the 2010 
National Cancer Patient Experience Survey in England 
report that almost 30% of 564 patients with renal cancer 
saw their general practitioner three or more times before 
hospital referral.21 Furthermore, the results from the 
charity Kidney Cancer UK (KCUK) 2018 patient survey 
showed that 22% of the 153 responders who presented to 
their General Practitioner or an Accident & Emergency 
department waited more than 3 months for a diagnosis.22 
The results of the KCUK survey (n=175 in total) extend 
further, with 51% of patients reporting their cancer being 
detected incidentally during imaging for an unrelated 
reason, and less than one- third (31%) having symptoms 
due to RCC, reflecting the findings from our own, much 
larger, study.
How then do we improve the rates of early diagnosis 
in kidney cancer? Raising awareness among the public to 
present early to their doctor, even with vague symptoms 
may seem logical, as well as increasing awareness with 
primary care teams. But many patients remain asymptom-
atic until they have advanced stage disease, and the PPVs 
for symptoms other than haematuria, such as pain and 
fatigue, are even lower than 1%,9 placing an impossible 
demand on general practitioners, who are required to 
act as gatekeepers to secondary care. The 5- year survival 
rates for kidney cancer in the UK lag behind the Euro-
pean average which may be related to differences in stage 
at diagnosis.23 Greater availability of point- of- care ultra-
sound may make a significant impact but its use varies 
widely across Europe and has not been widely adopted 
in the UK, with potential barriers in terms of time and 
training.24
Interest in exploring the potential for kidney cancer 
screening is growing,8 25 particularly given the signifi-
cant predicted rise in incidence.2 The potential cost- 
effectiveness of performing a single, renal focused, 
ultrasound scan among asymptomatic 60- year- old men 
has recently been reported.26 However, numerous uncer-
tainties still exist, in terms of who to screen, with what 
modality, as well as unknowns in terms of associated 
harms vs benefit.27 This is an area that clearly warrants 
further research. The identification of robust diagnostic 
biomarkers either in the serum or urine of patients that 
could be used to easily rule in or out the presence of RCC 
is another priority area for study,28 with recent promising 
reports in the literature,29 although still requiring signifi-
cant further validation and improved performance.
The strengths of this study include its prospective multi-
centre design, among a contemporary cohort of patients 
with robust linked clinicopathological and outcome data. 
The eligibility criteria for the study were broad and we 
believe our patient cohort to be largely representative, 
when considered at a population level (for comparisons 
by age, sex, stage and RCC type see online supplemen-
tary table 2). It is possible that the proportion of patients 
in our study with stage IV disease may be slightly lower 
than in the true population, reflecting differences in 
the clinical pathway these patients may take, which may 
have impacted on our reported rate of incidental diag-
nosis. Furthermore, not all patients seen at participating 
centres with suspected RCC during the study period were 
recruited to the study and, overall, we acknowledge that 
our cohort size reflects only a small proportion (less 
than 10%) of all patients diagnosed with RCC in the UK 
during the study period. A further limitation is the fact 
that patient- reported symptoms were recorded following 
referral to secondary care and there may, therefore, be 
some element of recall bias.
In summary, this study draws attention to the fact that 
reliance on symptoms for the early detection of kidney 
cancer is not robust. Our data suggest that improving 
public and professional awareness will have only a limited 
impact, and innovative biomarkers for this purpose remain 
to be identified. We suggest it is time to re- examine the 
case for screening looking at opportunities to link RCC 
screening into other programmes such as low dose CT 
scans for lung cancer health checks or ultrasound- based 
screening for abdominal aortic aneurysms.
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